CD8A and neoplasm: Flow cytometry analysis showed that a combination treatment of DSF/Cu and anti-PD-1 antibody increased the intratumoral infiltration of CD8+ T and NK cells (Fig. 6A-D), which serve as the primary effector cells in anti-tumor immunity.